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ABSTRACT
Memory T cell (TM) populations specific for transplantation Ags may arise from sensitization due to blood
transfusions, tissue transplants, or in multiparous females. In each of these scenarios, TM cells are likely
generated, and have been shown to persist in such individuals for extended time periods. Heightened resistance
to allogeneic marrow engraftment in certain individuals is therefore consistent with the presence of antidonor
TM. CD8 TM were generated against a single minor H Ag (MiHA) epitope to determine if such cells could
inhibit allogeneic marrow engraftment. The present results demonstrate that B6 mice sensitized to a single
immunodominant (H60) epitope efficiently reject donor marrow allografts expressing this MiHA alone or
together with multiple minor transplantation antigens, even following ablative TBI conditioning. To further
address the survival and function of these CD8 TM, sensitized mice were ablatively conditioned and admin-
istered a syngeneic HCT. CD8H60TCR TM were clearly detected up to 2 weeks later in such recipients.
Additionally, the memory cells present were capable of mediating effector responses as evidenced by their
ability to resist a second, allogeneic HCT. In summary, these observations highlight the increased risk of
resistance in the presence of antidonor antigen-specific CD8 TM due to their ability to survive and function
even following rigorous conditioning and HCT.
© 2007 American Society for Blood and Marrow Transplantation
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Recipient resistance to donor allogeneic hemato-
oietic progenitor and stem cells constitutes a major
arrier to successful engraftment. Experimental he-
atopoietic cell transplants (HCT) have demon-
trated that immune resistance can involve CD4,
D8, and NK populations [1-4]. Resistance to major
istocompatibility complex (MHC)-matched MiHA-
ismatched allogeneic marrow engraftment is efﬁ-
iently and rapidly mediated primarily by MiHA-re-
ctive T cells. Experimental and clinical studies have
eported that both CD8 and CD4 T cells can be
dentiﬁed in recipients during rejection of allogeneic
CT [5-8]. Because of their potent immunologicunction, long-lived host memory T cells (TM) could de particularly problematic with respect to donor al-
ogeneic hematopoietic engraftment. TM speciﬁc for
ransplantation antigens have been demonstrated after
lood transfusions, tissue transplants, or pregnancy
9-11]. Moreover, heterologous immune responses,
peciﬁcally those elicited by virus, have been shown to
nduce the generation of alloantigen reactive cells [12-
4]. Indeed, such viral immunity has been shown to
ugment the T cell immune barrier to tissue trans-
lants, and CD8 TM cell populations were identiﬁed
o be responsible for promoting this allograft rejection
14]. Therefore, multiple alloreactive CD8 TM pop-
lations capable of mediating resistance may be
resent in many transplant recipients. It remains to be
etermined how conditioning and transplant affect
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A. M. Shatry et al.294he survival and subsequent function of such CD8
M. To address this question, we utilized an estab-
ished preclinical MiHA-mismatched allograft trans-
lant model [15-17], taking advantage of a well-de-
ned donor MiHA, that is, H60 to monitor antigen-
peciﬁc CD8 TM in recipients following HCT
18,19]. Our ﬁndings demonstrate that antigen-spe-
iﬁc host CD8 TM were capable of surviving and
ffecting resistance despite ablative conditioning,
gainst donor hematopoietic grafts expressing H60
lone or together with multiple minor transplantation
ntigens. Moreover, the present results demonstrated
hat CD8 TM persist at least 2 to 3 weeks following
igorous conditioning, with the ability to mediate ef-
ector responses. Thus, these observations suggest
hat patients naturally or iatrogenically sensitized to
onor antigens could be at high risk of rejection of
llogeneic HCT.
ATERIALS AND METHODS
ice
Female C57BL/6 (B6) Ly5.1 and Ly5.2 mice (10-12
eeks old) were purchased from The Jackson Labora-
ory (Bar Harbor, ME). B6-Tg(ACTB-EGFP)1/Osb
B6-gfp) mice originally a gift from Dr. M. Okabe
Osaka University, Suita, Japan) were bred at the UM
nimal Facility. BALB.B mice were bred and maintained
t the UM Animal Facility. H60 congenic mice B6.
-H60c/Dcr were generated after 10 backcross genera-
ions as described [18].
60 Sensitization of Recipients Prior to HCT
Dendritic cells were generated ex vivo as described
20]. Brieﬂy, B6 marrow cells were cultured in RPMI
640 supplemented with 5% fetal bovine serum con-
aining 20 ng/mL rmGM-CSF and 20 ng/mL rmIL-4
or 5 days and then the cultures replenished with fresh
edia containing these cytokines for an additional 3
ays (GM-DC). The cells were washed, pulsed for 4
ours with 0.5 M of H60 peptide (LTFNYRNL),
nd 1-2  106 pulsed GM-DC were injected intra-
eritoneally to sensitize naïve female B6 Ly5.1 mice.
hree weeks after the second GM-DC injection, sen-
itized and naïve control female mice were ablatively
onditioned (9.0 Gy) and 24 hours later transplanted
ith sex-matched allogeneic BALB.B (H-2b), B6 H60
ongenic, or syngeneic B6 Ly5.2 T cell-depleted bone
arrow (TCD-BM).
ssessment of Peripheral Chimerism
nd Progenitor Cell Assay
The presence of H60-speciﬁc CD8 T cells (H60
D8TCR) was examined using H60 tetramer staining
n mice that had received H60-pulsed GM-DC. At 1
eek post-transplant, recipient PBMCs were analyzed nor donor chimerism by routine cytometric analysis
sing PE-anti-Ly9.1 (clone 30C7, Pharmingen), PE-
nti-CD45 (clone 104, Pharmingen), and gfp expres-
ion to detect BALB.B, B6 wild-type or B6-gfp donor
ells, respectively. CFU-IL3 assay was then performed
s previously described [15] using recipient spleen
ells to assess for the presence of committed hemato-
oietic progenitors. Progenitor colonies were enu-
erated (25 cells) and numbers expressed as
FU/2  106 spleen cells. The Students t test was
sed for statistical analysis.
ESULTS AND DISCUSSION
Tetramer-binding (H60) CD8 T cells were
eadily detectable in B6 mice sensitized with H60-
ulsed B6 GM-DC (Figure 1A). The frequency of
hese circulating CD8H60TCR cells was 1%
mong peripheral blood mononuclear cells (3%-5%
f CD8 T cells) consistent with that observed pre-
iously in B6 mice sensitized against BALB.B alloan-
igens [18]. To document the presence of CD8 TM,
irculating CD8H60TCR T cells in these mice were
nalyzed for the expression of markers characteristic
f CD8 TM (Figure 1A and [21]). The tetramer-
ositive CD8 T cells expressed both CD44 and Ly
C, indicating a CD8 TM phenotype. Thus, in B6
ice peptide-pulsed GM-DC generated CD8 TM
peciﬁc for the immunodominant epitope H60. Be-
ause we wanted to monitor this population in HCT
ecipients, sensitized mice were conditioned with
arying doses of TBI and assessed for CD8 TM sur-
ival. Results (Figure 1B) demonstrated that not only
ere these cells readily detectable in host spleen and
M early postconditioning and HCT, but appeared to
xhibit selective survival because they demonstrated
n increasing frequency among the CD8 T cell com-
artment with increasing doses of TBI. To determine
f these H60-speciﬁc CD8 TM could mediate resis-
ance to engraftment of MHC-matched allogeneic
arrow differing genetically only by H60, ablatively
onditioned naïve or sensitized B6 mice were trans-
lanted with B6-H60 congenic marrow grafts. Seven
ays post-HCT, the level of donor (H60) congenic
Ly 5.2) cells was 0.2% in these sensitized recipients
ompared to 4% in the naïve mice, indicating a 20-
old decrease in the presence of donor cells in sensi-
ized recipients (Figure 1C). Resistance was assessed
n sensitized recipients following HCT from BALB.B
hat express H60 as well as several subdominant
pitopes. Furthermore, splenic progenitor CFU-IL3
evels indicated that H60 sensitized recipients of con-
enic BM allografts contained signiﬁcantly fewer col-
nies compared to recipients of syngeneic marrow
rafts (Figure 2B). These observations support the
otion that recipients with CD8 TM speciﬁc for a
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MiHA-Specific CD8 TM and Resistance to Engraftment1MiHA-Specific CD8 TM and Resistance to Engraftment 295ingle MiHA epitope mediate resistance to allogeneic
onor marrow grafts.
Because clinically it is unlikely that only a single
iHA disparity will be extant between donor and recip-
ent, B6 recipients containing CD8 TM were adminis-
ered transplants with marrow disparate for multiple
iHA including the H60 locus. Peripheral donor chi-
erism analyzed at 1 and 2 weeks post-HCT indicated
hat the frequency of circulating donor (Ly9.1) cells in
60-sensitized recipients of BALB.B BM was 20 less
ompared to that present in naïve recipients (Figures 2A
nd 3). Similar to results in recipients of B6 H60 con-
enic marrow allografts, there was a marked reduction in
plenic CFU-IL3 levels 1 week post-HCT (Figure 2B).
herefore, although BALB.B cells expressed H60 anti-
en as well as additional MiHA epitopes [18], the re-
ponse of recipient CD8 T cells to the single H60
pitope was sufﬁcient to mediate resistance against trans-
lanted donor MHC-matched progenitor cells. These
esults indicate that host CD8 TM speciﬁc for a single
iHA epitope are not only able to survive ablative con-
itioning and marrow transplant, but that these cells
emain functional as demonstrated by their ability to
igure 1. Recipients containing CD8 TM speciﬁc for the single M
eneration of anti-H60 CD8 TM. B6 mice sensitized 2 with B6
irculating CD8H60TCR T cells 23 days following a booster inje
he TM markers CD44 and Ly 6C (A, histograms). (B). One wee
C-H60 sensitized B6 (CD45.1) mice ablatively conditioned (9.0 Gesist donor allografts. eLonger term survival of circulating host CD8
60TCR TM post-HCT was then examined. Sensi-
ized mice were ablatively conditioned and adminis-
ered a syngeneic HCT (Ly 5.1) to assess CD8 TM
ersistence in the absence of speciﬁc antigen. Two
eeks post-HCT, CD8H60TCR cells were clearly
etectable in the PBL of these recipients (Figure 4)
nd still comprised a signiﬁcant percentage of the
ost CD8 compartment. To assess functional capac-
ty of the surviving CD8 TM, these mice were
dministered a second round of conditioning (nona-
lative, 5.5 Gy) and then received an allogeneic
CT (Figure 5). Sensitized recipients of BALB.B
one marrow exhibited signiﬁcantly decreased
FU-IL3 numbers compared to naïve recipients of
hese grafts or to sensitized mice receiving synge-
eic B6-gfp marrow. These ﬁndings demonstrate
hat long-term, antigen-speciﬁc CD8H60TCR
M were not only readily detectable in the absence
f antigen 2 weeks following ablative conditioning
nd HCT, but were capable of surviving a second
ound of nonablative conditioning. Moreover, these
ells could also respond to antigen encounter and
epitope resist MHC matched allogeneic marrow engraftment. (A)
w-derived DC pulsed with H60 were analyzed for the presence of
ated CD8 H60TCR cells were analyzed for the expression of
HCT, peripheral donor chimerism (Ly 5.2, gfp) was analyzed in
transplanted with B6 H60 congenic 5  106 TCD-BM.iHA
marro
ction. G
k post-ffect an immune response as evidenced by resis-
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A. M. Shatry et al.296ance to allogeneic hematopoietic engraftment.
hus, the present ﬁndings indicate that prior al-
oantigenic encounter confers considerable risk for
he subsequent success of allogeneic bone marrow
ngraftment. First, memory cells would be typically
enerated, resulting in the presence of a more easily
ctivated T cell population. Moreover, the present
igure 2. Resistance by recipients with CD8 TM speciﬁc for a singl
r mice containing CD8H60 TM (B6DCH60) were transplanted
as analyzed at 1 week post-HCT. (B) Recipient spleen cells wer
ost-HCT (2 independent experiments).
igure 3. Resistance to MHC-matched allogeneic marrow in DC-
ensitized with marrow-derived DC pulsed with the H60 peptide w
onor chimerism (Ly9.1 or gfp) was analyzed 2 weeks post-HCT.
rom pooled mice (n  3-4/group).esults monitoring antigen-speciﬁc host CD8 T
ells clearly demonstrate that the memory subset
ffectively survives and functions at least several
eeks following signiﬁcant levels of conditioning.
ith respect to clinical HCT, the present ﬁndings
uggest that prior antigenic encounters that elicit
he generation of alloantigen reactive TM may
pe against MiHA-mismatched marrow allografts. (A) B6 naïve mice
 106 BALB.B BMC. Peripheral blood donor chimerism (Ly 9.1)
ed for the presence of committed progenitors (CFU-IL3) 1 week
nsitized B6 mice is evident 2 weeks post-HCT. Naïve or B6 mice
diated and transplanted as described in Figure 2. Peripheral blood
ers represent % of total cells gated by forward and side angle scattere epito
with 5
e assayH60 se
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MiHA-Specific CD8 TM and Resistance to Engraftment1MiHA-Specific CD8 TM and Resistance to Engraftment 297omplicate hematopoietic grafts dependent on the
onor HLA/non-HLA disparities.
H60 is an unusual MiHA in that the H60 protein
s a potent ligand for the activating NK receptor
KG2D [22,23] along with it encoding an immuno-
ominant CD8 T cell epitope [24]. However, it is very
nlikely that the observed resistance to donor allo-
rafts was a consequence of NK function of the H60
rotein because our immunization procedure only uti-
ized the immunodominant H60 CD8 T-cell peptide
pitope, and anti-NK1.1 mab failed to diminish resis-
ance in B6 mice transplanted with BALB.B marrow
ells [8]. Notably, the present ﬁndings also highlight
ifferences in postallogeneic HCT between host-
ersus-graft and graft-versus-host disease (GVHD).
igure 4. CD8H60TCR cell presence following ablative TBI co
ALB.B  106 syngeneic B6 Ly 5.1 BM-TCD. Fifteen days post-B
ells. Ly 5.2 cells were gated (inset) and analyzed for the presence
epresent % CD8H60TCR in gated cells.
igure 5. Memory cells present in sensitized recipients following
blative conditioning and HCT are capable of mediating effector
epsonses. Sensitized or unsensitized B6 mice were ﬁrst lethally (9.0
y) irradiated, and 24 hours later transplanted with 5  106 syn-
eneic TCD-BM. Twelve days following this ﬁrst HCT, the mice
ere irradiated with 5.5 Gy and transplanted 1 day later with 1 
07 BALB.B or B6-gfp TCD-BM. Ten days following this second
ransplant, mice were sacriﬁced and splenic CFU-IL3 analyzed.tegend represents donor-recipient combinations in 2nd transplant.hereas recognition of a single hematopoietic
pitope by host CD8 TM is apparently sufﬁcient to
licit resistance to MHC-matched allogeneic marrow
ngraftment, this same epitope is insufﬁcient to in-
uce clinical GVHD [25] (Roopenian et al, manu-
cript in preparation). This difference likely reﬂects
he limited expression of H60 to hematopoietic but
ot GVHD target tissues such as skin, liver, and the
ntestinal tract.
CD8 TM to speciﬁc MiHAs can be generated as a
onsequence of transfusion, tissue transplantation, or
regnancy, and subsequently persist lifelong [9-11].
oreover, CD8 TM to immunodominant epitopes,
uch as H60, are readily generated as a consequence of
ndirect presentation [24], increasing the probability
hat priming for the generation of TM will occur
egardless of whether sensitizing allogeneic cells were
r were not matched with donor at the MHC. Finally,
M generated as the result of viral/microbial encoun-
er expressing TCRs crossreactive with MHC alloan-
igens would mediate increased resistance to alloge-
eic marrow engraftment via such heterologous
mmunity [14,26]. It is therefore likely that greater
onor-recipient MiHA mismatches would result in a
igher probability of encountering endogenous host
D8 TM bearing antidonor allo-speciﬁc TCRs. Sur-
ival of CD8 TM even after ablative conditioning
ould be a result of their increased expression of
CL-2 [27] compared to naïve or effector cells ren-
ering CD8 TM more resistant to apoptosis [28].
onsidering there are increasing numbers of reduced
ntensity conditioning HCT, there will likely be
igher frequencies of surviving recipient CD8 TM
ing and synerneic BMT. Naïve (A) or B6 mice sensitized (B) with
ripheral blood was analyzed for recipient (Ly 5.2) CD8H60TCR
8 and H60 staining in naïve (A) or primed recipients (B). Numbersndition
MT, pe
of CDhat will constitute an even more formidable barrier
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A. M. Shatry et al.298o allogeneic marrow engraftment. Thus, strategies
imed at improving engraftment of MiHA-matched
llogeneic marrow should consider the risks posed by
ecipient CD8 TM populations.
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